news

EC approves RINVOQ (upadacitinib) to treat active psoriatic arthritis

20
SHARES

AbbVie’s RINVOQ (upadacitinib) has been approved in the EU to treat adult patients with active psoriatic arthritis (PsA).

RINVOQ to treat psoriasis

AbbVie has announced that the European Commission (EC) has approved RINVOQ (upadacitinib, 15mg), an oral, once daily selective and reversible JAK inhibitor for the treatment of active psoriatic arthritis (PsA). The treatment will be used in adult patients who have responded inadequately to or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

According to the company, RINVOQ may be used as monotherapy or in combination with methotrexate. The drug is also indicated for the treatment of active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy. The EC approval is supported by data from the three pivotal clinical trials SELECT-PsA 1, SELECT-PsA 2 and SELECT-AXIS 1, demonstrating RINVOQ’s efficacy across multiple measures of disease activity.

“Psoriatic arthritis and ankylosing spondylitis have a significant impact on many aspects of life for those living with these conditions,” said Dr Tom Hudson, Senior Vice President of R&D and Chief Scientific Officer of AbbVie. “We are proud to provide RINVOQ as a new treatment option to patients with PsA and a first-in-class treatment option to those living with AS. These approvals are important milestones in our commitment to develop a portfolio of solutions that advance standards-of-care for people living with rheumatic diseases.”

In both Phase III clinical trials, SELECT-PsA 1 and SELECT-PsA 2, RINVOQ met the primary endpoint at week 12 versus placebo in adults with active PsA who had an inadequate response to non-biologic DMARDs or biologic DMARDs, respectively. RINVOQ also achieved non-inferiority to adalimumab (40mg, every other week). Patients receiving RINVOQ experienced greater improvements in physical function and skin symptoms and a greater proportion achieved minimal disease activity (MDA) compared to those receiving placebo at week 24.

The marketing authorisation means that RINVOQ is approved in all member states of the EU, as well as IcelandLiechtenstein and Norway. RINVOQ is already approved for the treatment of adults with moderate to severe active rheumatoid arthritis.

Share via
Share via